Banys-Paluchowski Malgorzata, Ruckhäberle Eugen, Schütz Florian, Krawczyk Natalia, Fehm Tanja
Department of Gynecology and Obstetrics, Marienkrankenhaus Hamburg, Hamburg, Germany.
Department of Gynecology and Obstetrics, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany.
Geburtshilfe Frauenheilkd. 2017 Feb;77(2):142-148. doi: 10.1055/s-0043-100388.
Conventional chemotherapy is based on the "maximum tolerated dose" principle and aims at administering high doses of cytotoxic drugs followed by a rest period necessary for the body to recover. In the last decades alternative strategies have been developed to avoid serious side effects of conventional treatment, among them the metronomic chemotherapy. Much like a metronome keeps steady rhythm, metronomic therapy is administered continuously in low doses for a long time. In metastatic breast cancer, metronomic therapy is a valid option in pretreated or vulnerable patients and its use has recently been incorporated into various guidelines. In early breast cancer, the role of metronomic treatment remains to be clarified. A systematic review of PubMed/MEDLINE, ClinicalTrials.gov, the European Clinical Trials Database (EudraCT) and the Cochrane Database was conducted. In the present review, we discuss the current evidence on metronomic chemotherapy in non-metastatic breast cancer.
传统化疗基于“最大耐受剂量”原则，旨在给予高剂量的细胞毒性药物，随后是身体恢复所需的休息期。在过去几十年中，人们开发了替代策略以避免传统治疗的严重副作用，其中包括节拍化疗。就像节拍器保持稳定的节奏一样，节拍疗法以低剂量长时间持续给药。在转移性乳腺癌中，节拍疗法对于经预处理或身体虚弱的患者是一种有效的选择，其应用最近已被纳入各种指南。在早期乳腺癌中，节拍治疗的作用仍有待阐明。我们对PubMed/MEDLINE、ClinicalTrials.gov、欧洲临床试验数据库（EudraCT）和考科蓝数据库进行了系统综述。在本综述中，我们讨论了非转移性乳腺癌节拍化疗的当前证据。
